Related Experiment Video
Updated: Mar 31, 2026
08:49
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
1.5K
Beta-Blockers: Current State of Knowledge and Perspectives
Magdalena Ogrodowczyk1, Katarzyna Dettlaff, Anna Jelinska
1Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6,60-780 Poznan, Poland. mogrodo@ump.edu.pl.
Mini Reviews in Medicinal Chemistry
|October 17, 2015
Summary
Beta-blockers, like propranolol, have been used for over 50 years. Research continues to find new therapeutic uses for these essential cardiovascular drugs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Propranolol, the first beta-blocker, was developed over 50 years ago.
- Numerous beta-blocker compounds have since been synthesized and are in clinical use.
- The fundamental aspects of beta-blocker structure, function, pharmacokinetics, and mechanisms are well-established.
Purpose of the Study:
- To review the established knowledge on beta-blockers.
- To explore the evolving therapeutic applications of beta-blockers.
- To highlight the ongoing search for novel beta-blocking compounds and their potential uses.
Main Methods:
- Literature review of beta-blocker development and applications.
- Analysis of established pharmacological properties.
- Exploration of recent advancements and future research directions.
Main Results:
- Over half a century of beta-blocker development has yielded numerous clinically useful compounds.
- Established knowledge covers structure, function, pharmacokinetics, and mechanisms.
- Evolving research explores new therapeutic potentials, including known substances with beta-blocking properties.
Conclusions:
- Beta-blockers remain a cornerstone of cardiovascular medicine.
- Continuous research aims to expand their therapeutic utility.
- Future drug discovery may involve repurposing existing compounds with beta-blocking effects.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K